Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. However, ICIs are associated with potentially life-threatening immune-related adverse events (irAEs). Janus kinase inhibitors (JAKi) are a promising steroid-sparing agent…
Background
Cytokine release syndrome (CRS) is a life-threatening toxicity of chimeric antigen receptor T-cell therapy (CART) for B-cell acute lymphoblastic leukemia (B-ALL). Lower rates of severe CRS have been reported in patients treated with CD22-di…
Ovarian cancer (OC) remains one of the deadliest gynecologic malignancies, and, despite the presence of tumor-infiltrating lymphocytes (TILs) in nearly half of cases, immune checkpoint inhibitors have shown only modest clinical benefit. These observat…
Background
As a key downstream effector of the Hippo signaling pathway, Yes-associated protein (YAP) has emerged as a pivotal regulator of tumor immune evasion and resistance to immune checkpoint inhibitors (ICIs). However, the relationship between YA…
Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has represented a major advancement for the treatment of various cancers. Though ICB has been an effective tool in the clinical management of patients, a significant subset of indivi…
Background
This first-in-human clinical study explored lomvastomig, an immunoglobulin G1-based Fc-silenced bispecific antibody that simultaneously blocks the immune checkpoint receptors programmed cell death protein 1 (PD-1) and T-cell immunoglobulin …
T cell receptors (TCRs) are central to adaptive immunity, yet their vast sequence and structural diversity present a significant challenge to fully understand immune responses. The application of high-throughput sequencing technologies, including bulk…
Background
Melanoma shows one of the highest response rates to immune checkpoint inhibitors (ICIs), yet nearly half of patients experience primary or acquired resistance. While immune contexture strongly influences therapeutic efficacy, tumor cell-int…
Background
Chronic inflammation is a well-established driver of colorectal cancer (CRC), with the resulting inflammatory microenvironment facilitating tumor initiation and progression. The integrin CD11b/CD18, a leukocyte-specific heterodimeric adhesi…
Background
Anti-PD-1 monoclonal antibody (mAb) therapy promotes the emergence of new T cell clonotypes within tumors, suggesting de novo priming in the periphery. Yet, the mechanisms that mobilize these additional T cells remain poorly defined.
Metho…
